Intravitreal bevacizumab for age-related macular degeneration with good visual acuity

Background/Aim. Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab. Methods. The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin?). The total of three doses was given with a one-month interval between doses. Results. Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p < 0.001). The average central macular thickness (CMT) measured by OCT was improved from 474 ?m in the beginning to 341 ?m after the administration of all the three doses of the drug (p < 0.001). There were no side effects. Conclusions. Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD.

Download Full-text

Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration

Journal of Visual Impairment & Blindness ◽

10.1177/0145482x0810201004 ◽

2008 ◽

Vol 102 (10) ◽

pp. 600-610 ◽

Cited By ~ 43

Author(s):

Janet S. Sunness ◽

Gary S. Rubin ◽

Abraham Zuckerbrod ◽

Carol A. Applegate

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Geographic Atrophy ◽

Age Related Macular Degeneration ◽

Good Visual Acuity ◽

Age Related ◽

Foveal Sparing

Foveal-sparing scotomas are common in advanced dry macular degeneration (geographic atrophy). Foveal preservation may be present for a number of years. Despite good visual acuity, these patients have reduced reading rates. Magnification may not be effective if the text becomes too large to “fit” within the central spared area.

Download Full-text

Comparison of Visual Acuity and Central Macular Thickness in Neovascular Age-related Macular Degeneration Patients with Subretinal and Intraretinal Fluid Treated with Intravitreal Bevacizumab

Ophthalmologica Indonesiana ◽

10.35749/journal.v45i1.173 ◽

2019 ◽

Vol 45 (1) ◽

pp. 20

Author(s):

Novia Rahayu ◽

Elvioza Elvioza ◽

Aria Kekalih

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Intravitreal Bevacizumab ◽

Age Related Macular Degeneration ◽

Loading Dose ◽

Central Macular Thickness ◽

Neovascular Amd ◽

Age Related ◽

Bevacizumab Treatment ◽

Intraretinal Fluid

Purpose: To compare visual acuity (VA) and central macular thickness (CMT) outcome of loading dose intravitreal bevacizumab treatment between neovascular AMD patients with character of predominant subretinal and intraretinal fluid. Methods: Prospective study of loading dose intravitreal bevacizumab treated age-related macular degeneration, of which has a baseline macular morphology of subretinal or intraretinal fluid. VA, CMT, and their changes were evaluated during and after loading dose was completed. Results: Thirty eight eyes (38 patients, mean age 66,95 years) were enrolled. 20 eyes were in subretinal fluid (SRF group) and 18 intraretinal fluid (IRF) group. Mean VA at baseline eventually was significantly different where SRF group (56,41 letters) were better than IRF group (43,72 letters). No statistically significant difference of mean VA change or CMT change between group, however VA in SRF group remained higher and CMT in SRF group were lower than IRF group. Conclusion: Neovascular AMD, with both SRF and IRF at baseline, benefits from loading dose intravitreal bevacizumab treatment although mean visual acuity and mean central retinal thickness are better in those with SRF.

Download Full-text